Differing effects of rapamycin or calcineurin inhibitor on T-Regulatory cells in pediatric liver and kidney transplant recipients

American Journal of Transplantation

Volumn 12, Issue 12, 2012, Pages 3449-3461

  Akimova, T ^a   Kamath, B M ^b   Goebel, J W ^c   Meyers, K E C ^d   Rand, E B ^d   Hawkins, A ^c   Levine, M H ^e   Bucuvalas, J C ^c   Hancock, W W ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Clinical transplantation; immunoregulation; immunosuppression

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CD28 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CYCLOSPORIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 7 RECEPTOR; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS; TRANSCRIPTION FACTOR FOXP3;

ADOLESCENT; ANTIGEN EXPRESSION; ARTICLE; BLOOD; CHILD; CONTROLLED STUDY; DEMETHYLATION; DRUG EFFECT; FEMALE; GRAFT RECIPIENT; HUMAN; HUMAN CELL; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; METHYLATION; MONOTHERAPY; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE;

ADOLESCENT; CALCINEURIN; CASE-CONTROL STUDIES; CHILD; CROSS-SECTIONAL STUDIES; FEMALE; FOLLOW-UP STUDIES; FORKHEAD TRANSCRIPTION FACTORS; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LEUKOCYTES, MONONUCLEAR; LIVER TRANSPLANTATION; MALE; PROGNOSIS; SIROLIMUS; T-LYMPHOCYTES, REGULATORY; TRANSPLANTATION, HOMOLOGOUS;

EID: 84870570002     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2012.04269.x     Document Type: Article

References (30)

1. Srinivas TR, Kaplan B,. Transplantation in 2011: New agents, new ideas and new hope. Nature Rev Nephrol 2012; 8: 74-75.
2. Boros P, Bromberg JS,. Human FOXP3+ regulatory T cells in transplantation. Am J Transplant 2009; 9: 1719-1724.
3. Penninga L, Wettergren A, Chan AW, Steinbruchel DA, Gluud C,. Calcineurin inhibitor minimisation versus continuation of calcineurin inhibitor treatment for liver transplant recipients. Cochrane Database Syst Rev 2012; 3: CD008852.
4. Zeiser R, Nguyen VH, Beilhack A, et al,. Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production. Blood 2006; 108: 390-399.
5. Gao W, Lu Y, El Essawy B, Oukka M, Kuchroo VK, Strom TB,. Contrasting effects of cyclosporine and rapamycin in de novo generation of alloantigen-specific regulatory T cells. Am J Transplant 2007; 7: 1722-1732.
6. Wang H, Zhao L, Sun Z, Sun L, Zhang B, Zhao Y,. A potential side effect of cyclosporin A: Inhibition of CD4(+)CD25(+) regulatory T cells in mice. Transplantation 2006; 82: 1484-1492.
7. Segundo DS, Ruiz JC, Izquierdo M, et al,. Calcineurin inhibitors, but not rapamycin, reduce percentages of CD4+CD25+FOXP3+ regulatory T cells in renal transplant recipients. Transplantation 2006; 82: 550-557.
8. Chu Z, Zhang J, Zhao Y, et al,. Influence of immunosuppressive drugs on the development of CD4(+)CD25(high) Foxp3(+) T cells in liver transplant recipients. Transplant Proc 2010; 42: 2599-2601.
9. Ruggenenti P, Perico N, Gotti E, et al,. Sirolimus versus cyclosporine therapy increases circulating regulatory T cells, but does not protect renal transplant patients given alemtuzumab induction from chronic allograft injury. Transplantation 2007; 84: 956-964.
10. Lin WX, Christiansen D, Fu LL, Roberts MA, Sandrin MS, Ierino FL,. Foxp3(+) T cells in peripheral blood of renal transplant recipients and clinical correlations. Nephrology (Carlton) 2012; 17: 415-422.
11. Akimova T, Ge G, Golovina T, et al,. Histone/protein deacetylase inhibitors increase suppressive functions of human FOXP3+ Tregs. Clin Immunol 2010; 136: 348-363.
12. Akimova T, Beier UH, Wang L, Levine MH, Hancock WW,. Helios expression is a marker of T cell activation and proliferation. PLoS One 2011; 6: e24226.
13. Wieczorek G, Asemissen A, Model F, et al,. Quantitative DNA methylation analysis of FOXP3 as a new method for counting regulatory T cells in peripheral blood and solid tissue. Cancer Res 2009; 69: 599-608.
14. Mantel PY, Ouaked N, Ruckert B, et al,. Molecular mechanisms underlying FOXP3 induction in human T cells. J Immunol 2006; 176: 3593-3602.
15. Joffre O, Santolaria T, Calise D, et al,. Prevention of acute and chronic allograft rejection with CD4+CD25+Foxp3 +regulatory T lymphocytes. Nat Med 2008; 14: 88-92.
16. Wang J, Ioan-Facsinay A, van der Voort EI, Huizinga TW, Toes RE,. Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells. Eur J Immunol 2007; 37: 129-138.
17. Koshiba T, Li Y, Takemura M, et al,. Clinical, immunological, and pathological aspects of operational tolerance after pediatric living-donor liver transplantation. Transplant Immunol 2007; 17: 94-97.
18. Martinez-Llordella M, Puig-Pey I, Orlando G, et al,. Multiparameter immune profiling of operational tolerance in liver transplantation. Am J Transplant 2007; 7: 309-319.
19. Louis S, Braudeau C, Giral M, et al,. Contrasting CD25hiCD4+T cells/FOXP3 patterns in chronic rejection and operational drug-free tolerance. Transplantation 2006; 81: 398-407.
20. Martinez-Llordella M, Lozano JJ, Puig-Pey I, et al,. Using transcriptional profiling to develop a diagnostic test of operational tolerance in liver transplant recipients. J Clin Invest 2008; 118: 2845-2857.
21. He Q, Fan H, Li JQ, Qi HZ,. Decreased circulating CD4+CD25highFoxp3+ T cells during acute rejection in liver transplant patients. Transplant Proc 2011; 43: 1696-1700.
22. Perrella O, Sbreglia C, Arenga G, et al,. Acute rejection after liver transplantation: Is there a specific immunological pattern Transplant Proc 2006; 38: 3594-3596.
23. Demirkiran A, Kok A, Kwekkeboom J, et al,. Low circulating regulatory T-cell levels after acute rejection in liver transplantation. Liver Transplant 2006; 12: 277-284.
24. Akl A, Jones ND, Rogers N, et al,. An investigation to assess the potential of CD25highCD4+ T cells to regulate responses to donor alloantigens in clinically stable renal transplant recipients. Transplant Int 2008; 21: 65-73.
25. Ashton-Chess J, Dugast E, Colvin RB, et al,. Regulatory, effector, and cytotoxic T cell profiles in long-term kidney transplant patients. J Am Soc Nephrol 2009; 20: 1113-1122.
26. Dijke IE, Korevaar SS, Caliskan K, et al,. Inadequate immune regulatory function of CD4+CD25bright+FoxP3+ T cells in heart transplant patients who experience acute cellular rejection. Transplantation 2009; 87: 1191-1200.
27. Aerts NE, Dombrecht EJ, Ebo DG, Bridts CH, Stevens WJ, De Clerck LS,. Activated T cells complicate the identification of regulatory T cells in rheumatoid arthritis. Cell Immunol 2008; 251: 109-115.
28. Alonso-Arias R, Suarez-Alvarez B, Lopez-Vazquez A, et al,. CD127(low) expression in CD4+CD25(high) T cells as immune biomarker of renal function in transplant patients. Transplantation 2009; 88: S85-93.
29. Braudeau C, Racape M, Giral M, et al,. Variation in numbers of CD4+CD25highFOXP3+ T cells with normal immuno-regulatory properties in long-term graft outcome. Transplant Int 2007; 20: 845-855.
30. Kreijveld E, Koenen HJ, van Cranenbroek B, van Rijssen E, Joosten I, Hilbrands LB,. Immunological monitoring of renal transplant recipients to predict acute allograft rejection following the discontinuation of tacrolimus. PLoS One 2008; 3: e2711.